InspireMD Inc
NASDAQ:NSPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
EKI Energy Services Ltd
BSE:543284
|
IN |
|
Pilot Corp
TSE:7846
|
JP |
|
B
|
Berling SA
WSE:BRG
|
PL |
|
IDEX Corp
NYSE:IEX
|
US |
|
Witz Corp
TSE:4440
|
JP |
|
Japan Real Estate Investment Corp
TSE:8952
|
JP |
InspireMD Inc
Total Current Liabilities
InspireMD Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InspireMD Inc
NASDAQ:NSPR
|
Total Current Liabilities
$10.8m
|
CAGR 3-Years
40%
|
CAGR 5-Years
33%
|
CAGR 10-Years
4%
|
|
|
N
|
Nissan Medical Industries Ltd
TASE:NISA
|
Total Current Liabilities
₪274.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
A
|
Allmed Solutions Ltd
TASE:ALMD
|
Total Current Liabilities
₪2.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-8%
|
|
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
See Also
What is InspireMD Inc's Total Current Liabilities?
Total Current Liabilities
10.8m
USD
Based on the financial report for Sep 30, 2025, InspireMD Inc's Total Current Liabilities amounts to 10.8m USD.
What is InspireMD Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
4%
Over the last year, the Total Current Liabilities growth was 49%. The average annual Total Current Liabilities growth rates for InspireMD Inc have been 40% over the past three years , 33% over the past five years , and 4% over the past ten years .
